Vitamin D (VD) deficiency has been suggested as a risk factor for cancer. One recognized mechanism is that the low-serum 25-hydroxyvitamin D (25(OH)D) of VD deficiency reduces intratumoral 25(OH)D conversion to 1a,25-dihydroxyvitamin D (1,25D, the hormonal form of VD), compromising 1,25D-VD receptor (VDR) antitumoral actions. Reduced tumoral VDR and increased CYP24A1, the enzyme that degrades 1,25D and 25(OH)D, further worsen cancer progression. Importantly, in cells expressing CYP27A1 and/or CYP2R1, which convert inert VD into 25(OH)D, low-serum VD may reduce intratumoral 25(OH)D synthesis thereby compromising VDR antitumoral actions because 25(OH)D can activate the VDR directly and enhance 1,25D-VDR action. Therefore, this study examined whether abnormal endometrial expression of CYP27A1 and/or CYP2R1 may impair VDR-antiproliferative properties in endometrial carcinoma (EC). Immunohistochemical analysis of tissue microarrays of normal human endometrium (NE; n ¼ 60) and EC (n ¼ 157) showed the expected lower VDR expression in EC (P ¼ 0.0002). Instead, CYP24A1 expression was lower in EC compared with NE, while CYP27A1 and CYP2R1 expressions were higher (P ¼ 0.0002; P ¼ 0.03). Furthermore, in NE and EC, CYP2R1 and CYP27A1 expression correlated directly with nuclear VDR levels, an indicator of ligand-induced VDR activation, and inversely with the proliferation marker Ki67. Accordingly, in the endometrioid carcinoma cell lines IK, RL95/2 and HEC1-A, which express VDR, CYP27A1, and CYP2R1, VD efficaciously reduced cell viability and colony number, with a time course that paralleled actual increases in both intracellular 25(OH)D and nuclear VDR levels. Thus, VD may protect from EC progression in part through increased intratumoral 25(OH)D production by CYP27A1 and CYP2R1 for autocrine/paracrine enhancement of 1,25D-VDR-antiproliferative actions. Endometrial carcinoma (EC) results from neoplastic transformation of normal endometrium (NE) 1 leading to two main clinicopathological variants: endometrioid carcinoma (EEC) and non-endometrioid carcinomas (NEEC). EECs are estrogen-related tumors, frequently well differentiated, and developing mostly in peri-and postmenopausal women. Low grades (1 and 2) tumors are usually confined to the uterus (stage I) while grade 3 EECs are less frequent, with a higher tendency for extrauterine spread. NEEC, either serous or clear cell (CC) carcinomas, occur in older women, are estrogenunrelated tumors, with aggressive behavior and frequent extrauterine spread to the peritoneum or lymph nodes. 2, 3 One risk factor for human cancer that can be safely modified is vitamin D (VD) deficiency/insufficiency.
preclinical and clinical studies demonstrated that 1,25-dihydroxyvitamin D (1,25D, the most active endogenous VD metabolite and a potent steroid hormone) and/or its less calcemic synthetic analogs are efficacious, preventive, and therapeutic anticancer agents. [5] [6] [7] [8] However, cholecalciferol (VD 3 ) and its homolog in plants, ergocalciferol (VD 2 ), are inactive compounds that require bioactivation to exert their biological actions. In mammals (Figure 1) , the inactive cholecalciferol, synthesized from its precursor, 7-dehydrocholesterol through skin exposure to UVB light, is first 25-hydroxylated mainly in the liver by either mitochondrial CYP27A1 or microsomal CYP2R1. In humans, CYP2R1 is the most critical VD-25-hydroxylase, as mutations in this enzyme, but not in CYP27A1, cause VD insuficiency, 9 defined as serum 25-hydroxyvitamin D (25(OH)D) below 20 ng/ml. 10, 11 The final 1a-hydroxylation of 25(OH)D to produce 1,25D is catalyzed by mitochondrial CYP27B1, mainly in the kidney. 1,25D biological actions require 1,25D binding to the cytosolic VD receptor (VDR), which translocates to the nucleus and acts as a transcriptional regulator of the expression of more than 200 genes controlling normal and cancer cell growth, differentiation, DNA repair, apoptosis, angiogenesis, and metastatic potential. [12] [13] [14] The endometrium is a target of 1,25D/VDR antitumoral actions: in the EEC cell lines, IK, HEC-1A, and RL-95/2, 1,25D treatment induces differentiation, growth arrest, 15 and apoptosis. 16 Importantly, the increased risk for colorectal, 17 breast, 18 and prostate 8, 19 cancer in VD-deficient individuals is not the result of defective renal 1,25D synthesis because serum 1,25D, mostly of renal origin, remains normal until serum 25(OH)D levels decrease below 4 ng/ml. 20 Instead, during VD deficiency, low serum 25(OH)D limits 1,25D production by numerous non renal cells expressing CYP27B1 21 thus impairing local VDR antiproliferative actions.
Normal human endometrial cells express CYP27B1, 22 whose increases during pregnancy result in higher serum 1,25D to meet the enhanced calcium requirements. 23, 24 However, in the course of human cancer, several mechanisms worsen the defective local 1,25D synthesis and VDR antitumoral actions induced by VD deficiency aggravating tumor progression. These include: (a) reductions in VDR and CYP27B1 expression; (b) the appearance of CYP27B1 splicing variants, 25 and (c) increases in CYP24A1, the enzyme that degrades both 1,25D and its precursor 25(OH)D. [26] [27] [28] Indeed, the VDR-null mice has higher propensity for premalignant lesions in the descending colon than heterozygous VDR þ / À or wild-type mice. 29 Also, increases in CYP24A1 were associated to poor prognosis in high-grade colonic, 30 pulmonary, ovarian, 31 and breast tumors. 32 A novel mechanism may also link VD deficiency with higher cancer risk: defective local VD activation to 25(OH)D in cells expressing CYP27A1 or CYP2R1, as breast and prostate cells, 12 because locally produced 25(OH)D can activate the VDR directly, 33, 34 and also enhance 1,25D/VDR growth inhibition, as in prostate cancer cell lines. The former has been conclusively demonstrated in cells from the CYP27B1-null mice, unable to convert 25(OH)D to 1,25D, 
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L Bergadà et al and also in various cell types using either specific inhibition of the 1-hydroxylation of 25(OH)D, 33, 35 or VD metabolites that cannot be 1-hydroxylated. 36 However, the potency of 25(OH)D-bound VDR is at least 100-fold lower than that of 1,25D-bound VDR. Because EC cells express CYP27A1, 37 this study examined whether a defective endometrial conversion of VD 3 to 25(OH)D may contribute to alter 1,25D/VDR control of normal and cancerous endometrial growth. To this end, CYP27A1 and CYP2R1 expression was examined in proliferative vs secretory NE, and also in EC using human tissue microarrays (TMAs), and correlated with nuclear VDR, a marker of VDR activation, with the cell proliferation marker Ki67, and with physiological, prognostic, and clinicopathological data. The accuracy of TMA analyses in reflecting the ability of EC cells to convert VD into 25(OH)D to induce VDR translocation to the nucleus and growth arrest was directly assessed using VD treatment of IK, HEC-1A, and RL-95/2 cells, which derive from EEC, the prevalent EC in our population, after demonstrating that these 1,25D-responsive cells also express CYP27A1 and CYP2R1. The second TMA was composed of 95 EC and a third TMA containing 62 specimens from EC and their adjacent NE was also included in the study. All the samples were histologically reviewed and representative areas were marked in the corresponding paraffin blocks. Two selected cylinders (0.6 mm diameter) from two different areas were included in each EC case.
MATERIALS AND METHODS

Immunohistochemical Study
Sample sections of 3 mm were blocked for endogenous peroxidase and incubated with primary antibodies: VDR (1:1000), CYP27A1 (1:500), CYP2R1 (1:300) (Abcam). CYP24A1 (1:100, Sigma), and Ki67 (Ready To Use (RTU), DAKO). The reaction was visualized with the EnVision FLEX Detection Kit (DAKO). Sections were counterstained with haematoxylin. Immunohistochemical results were evaluated by two pathologists following uniform preestablished criteria. Staining intensity and % positive cells were graded semiquantitatively. Histological scores were obtained from each sample as follows: histoscore ¼ 1 Â (% light staining) þ 2 Â (% moderate staining) þ 3 Â (% strong staining), which ranged from 0 (no immunoreaction) to 300 (maximum immunoreactivity). The reliability of such scores for interpretation of immunohistochemical staining in EC TMAs has been shown previously. 38 All statistical comparisons used the average histoscore from the two different tumor cylinders for each specimen included in the TMAs.
Statistical Analysis
The levels of VDR, CYP27A1, CYP2R1, and CYP24A1 are described by their respective range, mean, and s.d. For each biomarker, we assessed differences between endometrial cycle Chemical Reagents VD 3 (cholecalciferol) was obtained from Sigma. VD 3 stock (4.5 M in 100% ethanol) was accepted qualitatively when the ratio of the absorbances at 265 and 228 nm was higher than 1.6. The concentration was calculated from the ratio of the absorbance at 265 nm and the VD 3 molar extinction coefficient (18, 200) . 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was from Sigma.
Cell Viability Assays EC cell viability after VD 3 treatment, at doses from 2 to 10 mM for 24, 48, or 72 h was measured using MTT assays following the manufacturer's instructions, and quantified by measuring the absorbances at 595 and 620 nm using a spectrophotometer (Bio-Rad, Richmond, USA).
Clonogenic Assay EC cells were seeded onto 6-well plates at a concentration of IK: 10 4 cells, RL-95/2, and HEC-1-A: 2 Â 10 4 cells per 1.5 ml of media. Cells were treated with vehicle or VD 3 (2-10 mM) for 48 h. Clonogenic capacity was obtained as previously described in Bergada et al. 39 Western Blot Analysis Nuclear and cytoplasmic extracts were obtained with the NE-PER nuclear and cytoplasmic extraction kit (Pierce, Rockford, USA). Protein concentrations were determined 40 Samples were spun down at 2500 r.p.m. for 10 min to obtain the supernatants containing VD metabolites and dried for 2 h under vacuum. The remaining solution was subjected to a 2-step liquidliquid extraction with ethyl acetate, as described in Ding et al. 41 The pooled upper phases were dried under nitrogen and intracellular 25(OH)D was measured by the Liason Assay.
Immunofluorescent Quantification of Nuclear VDR Translocation After the indicated treatment with VD 3 , IK cells were washed with PBS and fixed for 10 min with 4% paraformaldehyde ligand. 42 In NE from premenopausal women (average age ¼ 43), cytoplasmic and nuclear VDR expression was heterogeneous and significantly decreased in the proliferative endometrium compared with the secretory phase (Figure 2 ; Tables 1A and 1B) . As expected, Ki67 Hscores accurately reflected the changes in proliferation rates ( Table 2 ). The expression of the two main 25-hydroxylases for VD activation to 25(OH)D also changed in the cycling NE. The proliferative NE showed very mild or absent cytoplasmic CYP27A1 staining, which doubled in the secretory phase, although with no statistical significance (P ¼ 0.06) ( Table 3 ; Figure 2 ). The glandular epithelium also showed a mild and possibly artifactual CYP27A1 nuclear staining.
CYP2R1 immunoexpression was also cytosolic and low in endometrial glands during the proliferative phase with no stromal staining, and increased by 4.3-fold in the secretory endometrial glands (Table 4) , with a very low staining in endometrial stroma.
Systemically, the 1,25D-VDR complex induces CYP24A1 to degrade circulating excess of 1,25D or its precursor 25(OH)D in order to avoid VD toxicity. 42 In NE, the higher VDR HScore in epithelial cells of the secretory NE coincided with higher cytosolic CYP24A1 expression (Table 5, Figure 2 ).
More significantly, Table 6 shows that nuclear VDR levels correlated inversely with the marker of cell proliferation Ki67. Furthermore, two significant correlations were found between CYP27A1 and CYP2R1 expression, one direct with nuclear VDR expression, a marker of VDR activation, and one inverse with Ki67, which support a physiological role for local 25(OH)D production in VDR antiproliferative actions throughout the endometrial cycle. Furthermore, not only CYP24A1 expression correlated directly and strongly with nuclear VDR expression, but also with the cytosolic expression of both CYP27A1 and CYP2R1, thus supporting a role for both 25(OH)D-producing enzymes in VDR activation of CYP24A1 expression. 
Local vitamin D actions in endometrial cancer L Bergadà et al
Taken together, these results demonstrate that the NE is capable of full activation of inert VD to 1,25D. As CYP27B1 expression remains unchanged throughout the endometrial cycle, 22 these results also suggest that the changes in 25(OH)D synthesis along the endometrial cycle may be stronger regulators of VDR control of proliferation rates and CYP24A1 expression than local 1,25D synthesis.
Abnormalities in VD Local Control of Proliferation Rates in EC
Similar to other human cancers, Table 1A and Figure 2 show that EC samples elicited a significantly decreased nuclear VDR expression compared with NE. Also, EEC had less nuclear VDR than NEEC, with no significant differences among histological grades or pathological stages. VDR was also observed in the cytoplasm of EC cells with a quite heterogeneous expression pattern (mean cytoplasm Hscore: 114; range: 0-285; see Table 1B ). Different from nuclear VDR levels, average cytosolic VDR did not differ between EC and NE. This finding and the lack of the correlation between cytosolic and nuclear VDR of NE suggest that, in EC, a defective VDR translocation to the nucleus may contribute to impaired VDR-antiproliferative actions.
Interestingly, also different from the proliferative NE, both 25-hydroxylases were significantly enhanced in EC. CYP27A1 expression was 11-fold higher than in NE (P ¼ 0.0000) (Table 3; Figure 2 ). EECs elicited a 30% higher CYP27A1 expression compared with NEECs, although nonstatistically significant (P ¼ 0.08). Also, there was only a mild, although not significant, trend for decreased CYP27A1 immunostaining in EC according to FIGO grades or with the severity in pathologic stages that only reached statistical significance for stage III tumors (P ¼ 0.003). Importantly, CYP27A1 expression in EC samples correlated significantly and inversely with Ki67 expression (r ¼ À 0.26; P ¼ 0.004; Table 6 ).
EC also showed a cytoplasmic and heterogeneous CYP2R1 immunoexpression, 1.3-fold higher than in NE in any of the phases of the endometrial cycle (P ¼ 0.005; Table 4) . No statistical differences were demonstrated in CYP2R1 expression among EC, with histological type, FIGO grade or pathological stage (Table 4) . Importantly, CYP2R1 correlated positively with nuclear VDR immunoexpression (r ¼ 0.19, P ¼ 0.04). To evaluate whether quantitative PCR could be a better tool to assess actual expression of 25-hydroxylases in EC, three representative samples of EC were selected, based on their Hscore for CYP27A1 close to the average of this group, that is 11-fold higher than in NE (Table 2) . Intriguingly, mRNA levels of CYP27A1 and CYP2R1 were very similar (CYP27A1: 1.49±2.56 vs CYP2R1: 1.74±2.89) despite their remarkable differences in average increases in protein expression.
Interestingly, in EC, CYP24A1 expression was significantly lower than in NE with a granular and heterogeneous expression pattern (Figure 2) , with levels 1.4 higher in NEECs compared with EECs, and with the highest expression in FIGO grade 3 ECs. No differences in CYP24A1 expression occurred among different pathological stages, but again, stage III and IV tumors showed the highest levels of CYP24A1 immunostaining (Table 5) . Furthermore, different from NE, there was no correlation between CYP24A1 and nuclear VDR expression, or with CYP27A1 or CYP2R1, suggesting a distinct, if any, ligand-activated VDR induction of CYP24A1 in EC.
Next, studies in EEC cell lines examined the actual role of enhanced CYP27A1 and CYP2R1 expression in the activation of VDR antiproliferative actions by locally produced 25(OH)D.
Functional Relevance of CYP27A1 and CYP2R1 Expression in VDR Antiproliferative Actions These in vitro studies were conducted exclusively in EC cell lines, because DNA profiling analysis revealed that the two normal, immortalized endometrial cell lines HES and hTERT EEC were HeLa cervical carcinoma and MCF7 breast cancer cells, respectively. 43 First, we examined whether the EC cell lines IK, HEC-1A, and RL-95/2 reported to respond to 1,25D with growth inhibition, 15, 16 expressed CYP27A1 and CYP2R1. Upon immunohistochemical staining confirming the expression of both 25-hydroxylases in the three cell lines (Figure 3) , dose response and time course studies examined the potential anti-proliferative effects of the local bioactivation of VD 3 to 25(OH)D. Cells were treated with concentrations of VD 3 ranging from 0 to 10 mmol/l for 24, 48, or 72 h. The results of MTT assays depicted in Figure 4a show Local vitamin D actions in endometrial cancer L Bergadà et al that all three cell lines reduced viability in response to VD 3 in a dose-and time-dependent manner. Maximal reduction of viability post treatment of 62% (IK), 52% (RL-95-2), and 55% (Hec-1A) occurred by 72 h of treatment with 10 mM VD 3 . The lack of a significant reduction in viable cells upon a 24 h exposure to 10 mM VD 3 suggests that VD is not directly responsible for the reduced survival. The time delay in the response to VD indicates that the conversion of VD to 25(OH)D is an essential step for the observed cell viability effect. Figure 4b shows that VD 3 treatment (0-10 mmol/l for 48 h) caused a dose-dependent decrease in the capacity of all three EC cell lines to form colonies.
These three cell lines are derived from EEC, but only IK cells are well differentiated as most of the EEC samples in our TMAs, and also elicited a higher response to VD. Therefore, time course studies were conducted in IK cells to evaluate the contribution of intracellular 25(OH)D synthesis and VDR translocation to the nucleus to VD antiproliferative actions. While in two independent experiments, there was no detectable intracellular 25(OH)D produced by 7 million IK cells exposed to 10 mM VD 3 for 0, 12 or 24 h, an average 1.24 ng of 25(OH)D were synthesized in 48 h. Figure 5 shows marked increases in nuclear VDR staining in IK cells only if exposed to VD 3 for at least 24 or 48 h. This VDR translocation was confirmed through western blot analysis of changes in 
DISCUSSION
This work constitutes the first demonstration of an enhancement of CYP27A1 and CYP2R1 expression in the secretory phase of the cycling NE and also in EC for autocrine/paracrine activation of VD to 25(OH)D for VDRantiproliferative actions. This provides new mechanistic understanding for VD supplementation strategies that efficaciously prevent/attenuate endometrial disorders associated with impaired VDR actions, including EC growth.
In NE, the secretory tissue elicited higher CYP27A1 and CYP2R1 expression than the proliferative tissue, that concurred with lower proliferation rates, as measured by Ki67 Hscores, and which correlated directly with elevations in nuclear VDR and with CYP24A1 induction. The latter is a classical ligand-activated VDR induction of gene transcription. The delineated changes in 25-hydroxylating capacity along the endometrial cycle, while CYP27B1 expression remains constant, 22 suggest that local 25(OH)D synthesis could be more relevant than 1,25D production for VDR control of NE cyclic growth. Therefore, customizing VD supplementation strategies throughout the endometrial cycle to achieve an appropriate local 25(OH)D production should improve 1,25D/VDR autocrine/paracrine regulation of genes controlling Th1/Th2 responses toward tolerance 37, 44 in endometriosis, or the increases in the HOXA10 gene, 45, 46 required to correct abnormalities in fertility due to embryo implantations defects. The direct correlation existing between the increases in 25-hydroxylating enzymes and CYP24A1 induction, the enzyme degrading the excess of active VD metabolites, also suggest that the NE mimics the systemic VD endocrine system in its tight self-regulation for protection against VD toxicity. 42 In EC, CYP27A1 and CYP2R1 expression were 11-and 1.3-fold higher than in NE, and did not decrease in more advanced stages. These sustained increases in 25-hydroxylating capacity with EC progression may partially compensate for the reductions in nuclear VDR, as suggested by the direct correlations between the Hscores for CYP27A1 and CYP2R1 with enhanced nuclear VDR and reduced Ki67. 
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L Bergadà et al Importantly, the maintenance of enhanced 25-hydroxylating capacity with EC progression could also compensate for reductions in 1-hydroxylating capacity. indeed, CYP27B1 was shown to increase only at early stages of nonendometrial cancer development, but decrease in more advanced stages. 10 The indirect evidence from TMAs data of a role for local 25(OH)D production to arrest growth in human EC was supported by the efficacy of treatment of EC cell lines with inactive VD 3 for 48 h in suppressing growth and colony formation. Furthermore, the time course for the antiproliferative effects of inactive VD 3 was parallel to actual increases in 25(OH)D synthesis by IK cells, causing maximal increases in nuclear VDR expression. As CYP2R1 has a higher physiological relevance to maintain normal VD status, 9 the mild 30% increase in its expression in EC could be relevant in attenuating intratumorally the impact of systemic VD deficiency on EC progression. 47 This study also demonstrates that CYP24A1 cytoplasmic expression was lower in EC than in NE suggesting a minor role, if any, for enhanced catabolism of VD metabolites in the early progression of EC in VD-deficient individuals. Similar findings were reported in other hormonal-regulated neoplasms. In prostate cancer 48 and in MCF-7 breast tumor cells, 49 CYP24A1 mRNA expression is downregulated in malignant lesions compared with adjacent histologically benign lesions. Herein, only the more aggressive types of Representative western blot analysis of VDR expression in whole-cell extracts, or in nuclear and cytosolic fractions (c) using 20 mg of total protein from IK cells treated for 48 h as indicated in panel a. Tubulin, LDH, and Histone 1 were used as specific markers of whole-cell extracts, cytosolic and nuclear fractions, respectively. ** indicates Po0.05 from t test analysis of two independent experiments with triplicate determinations per condition.
Local vitamin D actions in endometrial cancer L Bergadà et al EC, NEEC, grade 3 and stage III and IV tumors exhibited the highest CYP24A1 expression concurring with low nuclear VDR, thus supporting the association between the induction of CYP24A1 with poor prognosis reported for human esophagus and colon carcinoma. 50, 51 Clearly, in VDdeficient patients with advanced stages of EC, the induction of CYP24A1 expression could aggravate local 25(OH)D or 1,25D deficiency and the already defective VDR activation of antitumoral actions due to low VDR. Our study underscores several advantages in improving VD 3 supplementation strategies over exclusive interventions with the potent hormone 1,25D, or its analogs,in attenuating EC progression. Not only 1,25D inhibits endometrial CYP27B1 activity at physiological levels, 52 but also suppresses CYP2R1 expression in fibroblasts and prostate cancer cells. 53 Thus, 1,25D treatment could simultaneously compromise endometrial 1,25D production and aggravate systemic VD deficiency. Furthermore, as 25(OH)D synergyzes with 1,25D in the growth arrest induced by VDR activation 33 and has a 25-fold lower affinity for CYP24A1 than 1,25D, our findings also suggest that appropriate VD 3 supplementation could help reduce the doses of 1,25D or related compounds for the prevention and treatment of EC in low VDR-expressing tumors through several mechanisms, namely, reducing the induction of CYP24A1; increasing the activities of intratumoral CYP27A1, CYP2R1, and perhaps, synergizing with CYP27B1 activity for VDR activation. Undoubtedly, prospective clinical trials with examination of CYP27A1, CYP2R1, and CYP24A1 and VDR expression at diagnosis are necessary to obtain evidence-based recommendations for VD 3 supplementation strategies effective in attenuating EC progression and of the accuracy and sensitivity of these markers of endometrial VD metabolism in predicting clinical outcomes. 
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